Can amantadine therapy delay the onset of dementia in Parkinson's disease? Commentary

Nature Clinical Practice Neurology

Volumn 2, Issue 12, 2006, Pages 648-649

  Rajput, Alex ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINESTERASE INHIBITOR; MEMANTINE; PSYCHOTROPIC AGENT;

AGE DISTRIBUTION; CAREGIVER; COGNITION; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CONTROL; DISEASE SEVERITY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; MEDICAL RECORD; MINI MENTAL STATE EXAMINATION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 33751233576     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0322     Document Type: Short Survey

References (3)

1. Elbaz A et al. (2002) Risk tables for parkinsonism and Parkinsons disease. J Clin Epidemiol 55: 25-31
2. Aarsland D et al. (2003) Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch Neurol 60: 387-392
3. Tariot PN et al. (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291: 317-324